Article

Real-world strategies increase medication compliance

Compliance with medical regimens for glaucoma decreases over time, and patients receiving more than one medication have lower rates of compliance. Despite advances in glaucoma therapy, such as once-daily dosing and dosing aids, patient compliance has not improved, said Douglas J. Rhee, MD.

Chicago-Compliance with medical regimens for glaucoma decreases over time, and patients receiving more than one medication have lower rates of compliance. Despite advances in glaucoma therapy, such as once-daily dosing and dosing aids, patient compliance has not improved, said Douglas J. Rhee, MD.

Dr. Rhee, of Harvard Medical School, Boston, discussed some commonsense methods to help patients with glaucoma achieve higher rates of compliance with their treatment regimens.

He advised educating patients about the goals of treatment. An important point that he emphasized is that glaucoma drugs do not improve vision. The ophthalmologist is the patient’s best source of information, and he urges patients to visit the numerous Internet sites and read brochures to learn about glaucoma control.

Dr. Rhee also uses some simple approaches to improving compliance, such as prescribing drugs that require once-daily dosing or combination agents, and coupling the daily dosing with a daily activity, such as brushing one’s teeth or drinking coffee.

In addition, he prefers giving patients written instructions that use the same generic or trade name as that on their medication.

“This improves their level of understanding,” he said.

Because eye drop instillation is a well-recognized problem, Dr. Rhee has patients watch a video that demonstrates the correct method of instilling drops. Technicians are also involved with teaching patients.

“There is preliminary evidence that indicates that using this patient educator improves patient motivation and adherence to treatment and builds rapport with patients,” he said.

“Compliance with mediation regimens is a substantial barrier to medical therapy,” Dr. Rhee said. “Numerous tools are available that can help educate patients as much as possible. Educate patients about their disease, eye drop instillation, provide written instructions, minimize the cost and side effects, and simplify the regimens.”

For more articles in this issue of Ophthalmology Times Conference Briefclick here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.